Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors

Abstract Introduction Programmed death 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitors are proved to be promising and are applied for the treatment of a variety of solid tumors. This retrospective study evaluated the efficacy of PD‐1/PD‐L1 inhibitors in patients with advanced solid tumors and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Miao Wang, Hongchao Zhen, Xiaoyue Jiang, Yuting Lu, Yuhan Wei, Jiangtao Jin, Qin Li
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	advanced solid tumor clinical efficacy efficacy prediction immunotherapy PD‐1/PD‐L1 inhibitor Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/7e67fd62bbea405ca3ca1c424f2c1796
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7e67fd62bbea405ca3ca1c424f2c1796
record_format	dspace
spelling	oai:doaj.org-article:7e67fd62bbea405ca3ca1c424f2c17962021-11-12T19:57:15ZClinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors2050-452710.1002/iid3.511https://doaj.org/article/7e67fd62bbea405ca3ca1c424f2c17962021-12-01T00:00:00Zhttps://doi.org/10.1002/iid3.511https://doaj.org/toc/2050-4527Abstract Introduction Programmed death 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitors are proved to be promising and are applied for the treatment of a variety of solid tumors. This retrospective study evaluated the efficacy of PD‐1/PD‐L1 inhibitors in patients with advanced solid tumors and explore the effect of clinical characteristics on it. Materials and Methods From October 2017 to April 2020, a total of 90 patients from Capital Medical University Affiliated Beijing Friendship Hospital were enrolled. Results At a median follow‐up of 10.55 months, objective response was observed in 23 patients and the objective response rate was 25.6%. The median progression‐free survival (PFS) was 5.5 months (95% confidence interval [CI], 3.69–7.37). The 6m‐PFS was 45.8% and 12m‐PFS was 25.1%. The median overall survival (OS) was 16.9 months (95% CI, not reached [NR]‐NR). The 12m‐OS was 58.1% and 18m‐OS was 48.1%. Conclusion The efficacy of PD‐1/PD‐L1 inhibitors in the treatment of advanced solid tumors was comparable to previous studies. ECOG performance status, smoking status, liver metastasis, neutrophil‐to‐lymphocyte ratio were independently correlated with PFS while liver metastasis and lactate dehydrogenase level were independently correlated with OS.Miao WangHongchao ZhenXiaoyue JiangYuting LuYuhan WeiJiangtao JinQin LiWileyarticleadvanced solid tumorclinical efficacyefficacy predictionimmunotherapyPD‐1/PD‐L1 inhibitorImmunologic diseases. AllergyRC581-607ENImmunity, Inflammation and Disease, Vol 9, Iss 4, Pp 1584-1595 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	advanced solid tumor clinical efficacy efficacy prediction immunotherapy PD‐1/PD‐L1 inhibitor Immunologic diseases. Allergy RC581-607
spellingShingle	advanced solid tumor clinical efficacy efficacy prediction immunotherapy PD‐1/PD‐L1 inhibitor Immunologic diseases. Allergy RC581-607 Miao Wang Hongchao Zhen Xiaoyue Jiang Yuting Lu Yuhan Wei Jiangtao Jin Qin Li Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
description	Abstract Introduction Programmed death 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitors are proved to be promising and are applied for the treatment of a variety of solid tumors. This retrospective study evaluated the efficacy of PD‐1/PD‐L1 inhibitors in patients with advanced solid tumors and explore the effect of clinical characteristics on it. Materials and Methods From October 2017 to April 2020, a total of 90 patients from Capital Medical University Affiliated Beijing Friendship Hospital were enrolled. Results At a median follow‐up of 10.55 months, objective response was observed in 23 patients and the objective response rate was 25.6%. The median progression‐free survival (PFS) was 5.5 months (95% confidence interval [CI], 3.69–7.37). The 6m‐PFS was 45.8% and 12m‐PFS was 25.1%. The median overall survival (OS) was 16.9 months (95% CI, not reached [NR]‐NR). The 12m‐OS was 58.1% and 18m‐OS was 48.1%. Conclusion The efficacy of PD‐1/PD‐L1 inhibitors in the treatment of advanced solid tumors was comparable to previous studies. ECOG performance status, smoking status, liver metastasis, neutrophil‐to‐lymphocyte ratio were independently correlated with PFS while liver metastasis and lactate dehydrogenase level were independently correlated with OS.
format	article
author	Miao Wang Hongchao Zhen Xiaoyue Jiang Yuting Lu Yuhan Wei Jiangtao Jin Qin Li
author_facet	Miao Wang Hongchao Zhen Xiaoyue Jiang Yuting Lu Yuhan Wei Jiangtao Jin Qin Li
author_sort	Miao Wang
title	Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
title_short	Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
title_full	Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
title_fullStr	Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
title_full_unstemmed	Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
title_sort	clinical observation of the efficacy of pd‐1/pd‐l1 inhibitors in the treatment of patients with advanced solid tumors
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/7e67fd62bbea405ca3ca1c424f2c1796
work_keys_str_mv	AT miaowang clinicalobservationoftheefficacyofpd1pdl1inhibitorsinthetreatmentofpatientswithadvancedsolidtumors AT hongchaozhen clinicalobservationoftheefficacyofpd1pdl1inhibitorsinthetreatmentofpatientswithadvancedsolidtumors AT xiaoyuejiang clinicalobservationoftheefficacyofpd1pdl1inhibitorsinthetreatmentofpatientswithadvancedsolidtumors AT yutinglu clinicalobservationoftheefficacyofpd1pdl1inhibitorsinthetreatmentofpatientswithadvancedsolidtumors AT yuhanwei clinicalobservationoftheefficacyofpd1pdl1inhibitorsinthetreatmentofpatientswithadvancedsolidtumors AT jiangtaojin clinicalobservationoftheefficacyofpd1pdl1inhibitorsinthetreatmentofpatientswithadvancedsolidtumors AT qinli clinicalobservationoftheefficacyofpd1pdl1inhibitorsinthetreatmentofpatientswithadvancedsolidtumors
_version_	1718430326671278080

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors

Ejemplares similares